Literature DB >> 24782098

An exploratory study of serum creatinine levels in patients with amyotrophic lateral sclerosis.

Xueping Chen1, Xiaoyan Guo, Rui Huang, Zhenzhen Zheng, Yongping Chen, Hui-Fang Shang.   

Abstract

The etiology of amyotrophic lateral sclerosis (ALS) remains unknown, but existing data argue for a role of creatinine in ALS pathophysiology. Our aim is to clarify the correlation between serum creatinine and ALS in Chinese population. A total of 512 sporadic ALS (SALS) patients and 501 age- and gender-matched healthy controls were included. Revised ALS Functional Rating Scale (ALS-FRS-R) was used to assess the motor functional status of SALS patients. Survival analysis was performed using Kaplan-Meier method. Serum creatinine levels were significantly lower in SALS patients than in controls (p < 0.001). Patients with the second, the third and highest quartiles of creatinine levels had a significantly lower presence of ALS compared to those with the lowest quartile (p for trend <0.001). However, decreased presence of ALS was not found in the highest quartiles compared with the lowest quartiles in females. Sporadic ALS patients with different site of onset have similar serum creatinine levels, but underweight patients presented lower levels of serum creatinine. Patients with low serum creatinine levels are more likely to have severe motor impairment and low body mass index (BMI) values. This study demonstrates that SALS patients have lower serum creatinine levels than well-matched controls. Higher levels of serum creatinine are less likely to be associated with the presence of ALS in Chinese populations. Low serum creatinine levels may be related to severe motor impairment in SALS patients, after adjusting the confounding factor-BMI. However, serum creatinine has no deleterious impact on survival in ALS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24782098     DOI: 10.1007/s10072-014-1807-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  32 in total

1.  Reduction rate of body mass index predicts prognosis for survival in amyotrophic lateral sclerosis: a multicenter study in Japan.

Authors:  Toshio Shimizu; Utako Nagaoka; Yuki Nakayama; Akihiro Kawata; Chiharu Kugimoto; Yoshiyuki Kuroiwa; Mitsuru Kawai; Takayoshi Shimohata; Masatoyo Nishizawa; Ban Mihara; Hajime Arahata; Naoki Fujii; Reiko Namba; Hiroaki Ito; Takashi Imai; Keigo Nobukuni; Kiyohiko Kondo; Mieko Ogino; Takashi Nakajima; Tetsuo Komori
Journal:  Amyotroph Lateral Scler       Date:  2012-06

2.  Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation.

Authors:  Hicham Skali; Hajime Uno; Andrew S Levey; Lesley A Inker; Marc A Pfeffer; Scott D Solomon
Journal:  Am Heart J       Date:  2011-08-09       Impact factor: 4.749

3.  Biochemical alterations associated with ALS.

Authors:  Kay A Lawton; Merit E Cudkowicz; Meredith V Brown; Danny Alexander; Rebecca Caffrey; Jacob E Wulff; Robert Bowser; Robert Lawson; Matt Jaffa; Michael V Milburn; John A Ryals; James D Berry
Journal:  Amyotroph Lateral Scler       Date:  2011-11-25

4.  Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones.

Authors:  J P Simons; A M Schols; W A Buurman; E F Wouters
Journal:  Clin Sci (Lond)       Date:  1999-08       Impact factor: 6.124

5.  An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis.

Authors:  Stefano Zoccolella; Isabella Laura Simone; Rosa Capozzo; Rosanna Tortelli; Antonio Leo; Eustachio D'Errico; Giancarlo Logroscino
Journal:  J Neurol       Date:  2010-09-15       Impact factor: 4.849

6.  Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy.

Authors:  Laurence Viollet; Susan Gailey; David J Thornton; Neil R Friedman; Kevin M Flanigan; John D Mahan; Jerry R Mendell
Journal:  Muscle Nerve       Date:  2009-09       Impact factor: 3.217

7.  Prognosis and epidemiology of amyotrophic lateral sclerosis: Analysis of a clinic population, 1997-2011.

Authors:  Kim Traxinger; Crystal Kelly; Brent A Johnson; Robert H Lyles; Jonathan D Glass
Journal:  Neurol Clin Pract       Date:  2013-08

Review 8.  Prognostic factors in ALS: A critical review.

Authors:  Adriano Chiò; Giancarlo Logroscino; Orla Hardiman; Robert Swingler; Douglas Mitchell; Ettore Beghi; Bryan G Traynor
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

9.  Nutritional considerations in the management of patients with amyotrophic lateral sclerosis (ALS).

Authors:  L A Slowie; M S Paige; J P Antel
Journal:  J Am Diet Assoc       Date:  1983-07

10.  Clinical outcomes and serum uric acid levels in elderly patients with amyotrophic lateral sclerosis aged ≥ 70 years.

Authors:  Hiroshi Kataoka; Takao Kiriyama; Yasuyo Kobayashi; Hirosei Horikawa; Satoshi Ueno
Journal:  Am J Neurodegener Dis       Date:  2013-06-21
View more
  8 in total

1.  Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression.

Authors:  Robert Küffner; Neta Zach; Raquel Norel; Johann Hawe; David Schoenfeld; Liuxia Wang; Guang Li; Lilly Fang; Lester Mackey; Orla Hardiman; Merit Cudkowicz; Alexander Sherman; Gokhan Ertaylan; Moritz Grosse-Wentrup; Torsten Hothorn; Jules van Ligtenberg; Jakob H Macke; Timm Meyer; Bernhard Schölkopf; Linh Tran; Rubio Vaughan; Gustavo Stolovitzky; Melanie L Leitner
Journal:  Nat Biotechnol       Date:  2014-11-02       Impact factor: 54.908

Review 2.  Use of biomarkers in ALS drug development and clinical trials.

Authors:  Nadine Bakkar; Ashley Boehringer; Robert Bowser
Journal:  Brain Res       Date:  2014-10-24       Impact factor: 3.252

3.  Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach.

Authors:  Robert Kueffner; Neta Zach; Maya Bronfeld; Raquel Norel; Nazem Atassi; Venkat Balagurusamy; Barbara Di Camillo; Adriano Chio; Merit Cudkowicz; Donna Dillenberger; Javier Garcia-Garcia; Orla Hardiman; Bruce Hoff; Joshua Knight; Melanie L Leitner; Guang Li; Lara Mangravite; Thea Norman; Liuxia Wang; Jinfeng Xiao; Wen-Chieh Fang; Jian Peng; Chen Yang; Huan-Jui Chang; Gustavo Stolovitzky
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

4.  Serum Creatinine Protects Against Amyotrophic Lateral Sclerosis: a Mendelian Randomization Study.

Authors:  Mengmeng Wang; Dandan Liu; Zhizhong Zhang; Wei Xie; Liping Cao; Linfeng Zhu; Meng Liu; Shiying Sheng; Xuegan Lian
Journal:  Mol Neurobiol       Date:  2021-02-08       Impact factor: 5.590

5.  Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials.

Authors:  Ruben P A van Eijk; Marinus J C Eijkemans; Toby A Ferguson; Stavros Nikolakopoulos; Jan H Veldink; Leonard H van den Berg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-10-30       Impact factor: 10.154

Review 6.  Therapeutic antibodies - natural and pathological barriers and strategies to overcome them.

Authors:  Yara Al Ojaimi; Timothée Blin; Juliette Lamamy; Matthieu Gracia; Aubin Pitiot; Caroline Denevault-Sabourin; Nicolas Joubert; Jean-Pierre Pouget; Valérie Gouilleux-Gruart; Nathalie Heuzé-Vourc'h; Débora Lanznaster; Sophie Poty; Thomas Sécher
Journal:  Pharmacol Ther       Date:  2021-10-20       Impact factor: 13.400

7.  Analysis of routine blood parameters in patients with amyotrophic lateral sclerosis and evaluation of a possible correlation with disease progression-a multicenter study.

Authors:  Nora Hertel; Magdalena Kuzma-Kozakiewicz; Marta Gromicho; Julian Grosskreutz; Mamede de Carvalho; Hilmi Uysal; Reinhard Dengler; Susanne Petri; Sonja Körner
Journal:  Front Neurol       Date:  2022-07-27       Impact factor: 4.086

8.  Assessment of Therapeutic Response of Edaravone and Riluzole Combination Therapy in Amyotrophic Lateral Sclerosis Patients.

Authors:  Swapnil Samadhiya; Vijay Sardana; Bharat Bhushan; Dilip Maheshwari; Ravi Goyal
Journal:  Ann Indian Acad Neurol       Date:  2022-06-09       Impact factor: 1.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.